VivoSeq
Cardiovascular

Long QT Syndrome

1

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Long QT Syndrome is an early-stage landscape with 1 program across 2 companies. The most active players are Thryv Therapeutics, Inc., Gilead.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

29/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

Thryv Therapeutics, Inc.

1 program

PreclinicalGilead logo

Gilead

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical1

THRV-1268

Thryv Therapeutics, Inc.

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

7

clinical trials

Terminated2 · 29%
Unknown status2 · 29%
Completed2 · 29%
Recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

A Phase 2/3, Two-part, Dose-ranging, Adaptive Study to Evaluate Efficacy and Safety of THRV-1268 in Participants Diagnosed With Long QT Syndrome Type 2 (LQTS 2)
Recruiting·TThryv Therapeutics, Inc.·Preclinical·NCT07277582·64 enrolled
Mutation-specific Therapy for the Long QT Syndrome
Completed·—·Phase 2·NCT04581408·16 enrolled
Effect of Grapefruit on QT Interval in Healthy Volunteers and Patients With Congenital Long QT Syndrome
Completed·TTel-Aviv Sourasky Medical Center·N/A·NCT02680080·25 enrolled
Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3
Terminated·Gilead logoGilead·Phase 3·NCT02300558·41 enrolled
Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).
Terminated·TThryv Therapeutics, Inc.·Phase 1/2·NCT05906732·42 enrolled
Novel Form of Acquired Long QT Syndrome
Unknown status·NNarrows Institute for Biomedical Research·Phase 4·NCT04169100·25 enrolled
Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine
Unknown status·TTel-Aviv Sourasky Medical Center·Phase 2·NCT01728025·10 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)